The company’s U.S. and Canadian generics business will continue to operate under the Actavis name, the company said.
The merger of the two companies in a transaction valued at $70.5 billion created one of the largest 10 global pharmaceutical companies, with overall annual revenues of over $23 billion estimated for 2015.
Actavis has two entities in Romania: Actavis SRL (sales and marketing) and Actavis Operations.
Actavis operates on over 60 markets and owns more than 30 plants, with an annual capacity of 44 billion units.